|
FIND OUT IF YOU HAVE A CLAIM AGAINST THE MANUFACTURER
Rezulin, the brand name for troglitazone, was a prescription drug intended to help diabetics utilize insulin in the bloodstream. For
those with adult-onset (Type 2) diabetes with a built-in resistance to insulin, Rezulin was designed to reduce the amount of sugar produced by the liver and control the body’s blood sugar levels.
For more than 500,000 people with Type 2 Diabetes who received Rezulin, the drug was promoted as the alternative to daily insulin
injections. Warner-Lambert, the manufacturer of Rezulin, requested and received fast track approval of Rezulin, and the drug made its way through the quickest approval process for a diabetes drug
in the history of the Federal Drug Administration (FDA).
In October of 1997, there were 35 reports of liver damage related to Rezulin, two ending in death. These findings lead Warner-Lambert
to recommend that physicians monitor their patients’ liver condition by testing enzyme levels five times during the first year.
When this failed to prevent liver damage, Warner-Lambert raised the warning to ten exams for the first year.
On May 19, 2000, the FDA finally requested the withdrawal of Rezulin.
At that time, Rezulin was associated with 90 confirmed reports of liver failure and 63 deaths. Many people have suffered severe liver damage resulting in death or the need for a liver transplant.
It is feared that hundreds more have sustained permanent liver damage without even knowing it.
The symptoms of Rezulin-induced liver damage include jaundice (yellow skin or eyes), dark urine, nausea, vomiting, abdominal pain, fatigue,
and loss of appetite. These may be early signs of liver damage. Blood tests to monitor your liver function should be administered to determine if you have suffered any liver damage.
If you suspect that you have been injured through the use of Rezulin or have questions or concerns, please fill out a case information form.
|
